NM_005529.7:c.5294-674A>G

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_005529.7(HSPG2):​c.5294-674A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.167 in 152,152 control chromosomes in the GnomAD database, including 2,431 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.17 ( 2431 hom., cov: 32)

Consequence

HSPG2
NM_005529.7 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.999

Publications

5 publications found
Variant links:
Genes affected
HSPG2 (HGNC:5273): (heparan sulfate proteoglycan 2) This gene encodes the perlecan protein, which consists of a core protein to which three long chains of glycosaminoglycans (heparan sulfate or chondroitin sulfate) are attached. The perlecan protein is a large multidomain proteoglycan that binds to and cross-links many extracellular matrix components and cell-surface molecules. It has been shown that this protein interacts with laminin, prolargin, collagen type IV, FGFBP1, FBLN2, FGF7 and transthyretin, etc., and it plays essential roles in multiple biological activities. Perlecan is a key component of the vascular extracellular matrix, where it helps to maintain the endothelial barrier function. It is a potent inhibitor of smooth muscle cell proliferation and is thus thought to help maintain vascular homeostasis. It can also promote growth factor (e.g., FGF2) activity and thus stimulate endothelial growth and re-generation. It is a major component of basement membranes, where it is involved in the stabilization of other molecules as well as being involved with glomerular permeability to macromolecules and cell adhesion. Mutations in this gene cause Schwartz-Jampel syndrome type 1, Silverman-Handmaker type of dyssegmental dysplasia, and tardive dyskinesia. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014]
HSPG2 Gene-Disease associations (from GenCC):
  • Schwartz-Jampel syndrome type 1
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), G2P
  • Silverman-Handmaker type dyssegmental dysplasia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, ClinGen, Labcorp Genetics (formerly Invitae)
  • Schwartz-Jampel syndrome
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.89).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.35 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
HSPG2NM_005529.7 linkc.5294-674A>G intron_variant Intron 42 of 96 ENST00000374695.8 NP_005520.4 P98160

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
HSPG2ENST00000374695.8 linkc.5294-674A>G intron_variant Intron 42 of 96 1 NM_005529.7 ENSP00000363827.3 P98160

Frequencies

GnomAD3 genomes
AF:
0.167
AC:
25465
AN:
152034
Hom.:
2429
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0913
Gnomad AMI
AF:
0.0581
Gnomad AMR
AF:
0.160
Gnomad ASJ
AF:
0.195
Gnomad EAS
AF:
0.363
Gnomad SAS
AF:
0.344
Gnomad FIN
AF:
0.201
Gnomad MID
AF:
0.120
Gnomad NFE
AF:
0.183
Gnomad OTH
AF:
0.168
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.167
AC:
25477
AN:
152152
Hom.:
2431
Cov.:
32
AF XY:
0.170
AC XY:
12654
AN XY:
74370
show subpopulations
African (AFR)
AF:
0.0914
AC:
3795
AN:
41504
American (AMR)
AF:
0.160
AC:
2443
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.195
AC:
676
AN:
3468
East Asian (EAS)
AF:
0.363
AC:
1877
AN:
5166
South Asian (SAS)
AF:
0.342
AC:
1652
AN:
4824
European-Finnish (FIN)
AF:
0.201
AC:
2131
AN:
10598
Middle Eastern (MID)
AF:
0.126
AC:
37
AN:
294
European-Non Finnish (NFE)
AF:
0.183
AC:
12451
AN:
67994
Other (OTH)
AF:
0.171
AC:
362
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1091
2182
3273
4364
5455
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
288
576
864
1152
1440
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.178
Hom.:
4348
Bravo
AF:
0.161
Asia WGS
AF:
0.332
AC:
1151
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.89
CADD
Benign
0.69
DANN
Benign
0.69
PhyloP100
-1.0
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4654991; hg19: chr1-22184552; API